Drug Profile
Research programme: granulocyte colony-stimulating factor - Bolder BioTechnology
Alternative Names: BBT-018; G-CSF - Bolder BioTechnology; Long-acting G-CSF - Bolder BioTechnology; PEG-G-CSF - Bolder BioTechnology; PEG-granulocyte colony stimulating factor - Bolder BioTechnologyLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class Granulocyte colony-stimulating factors; Polyethylene glycols
- Mechanism of Action Immunomodulators; Neutrophil stimulants; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia; Radiation injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neutropenia in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Radiation-injuries in USA (SC, Injection)
- 09 Nov 2010 Preclinical development in Neutropenia and Radiation injuries is ongoing in USA